Drug utilization review

Global Pharmacy Benefit Management Research Report 2023: Market to Grow by Over $185 Billion by 2027 - Strategic Partnerships will be Key to Stay Competitive - ResearchAndMarkets.com

Retrieved on: 
Friday, July 28, 2023
Professional Services, Health, Insurance, Health Insurance, General Health, Pharmaceutical, Drug utilization review, Pharmacy, Partnership, Hospital, Negotiation, Navitus Bay wind farm, Organization, PBM, Strategic partnership, Pharmacist, Acquisition, Patient, Case management, Growth, Ferdinand Magellan, Health care, Renewable energy

The global pharmacy benefit management market has witnessed significant growth, reaching $579.25 billion in 2023 with a robust compound annual growth rate (CAGR) of 7.0%.

Key Points: 
  • The global pharmacy benefit management market has witnessed significant growth, reaching $579.25 billion in 2023 with a robust compound annual growth rate (CAGR) of 7.0%.
  • Pharmacy benefit management involves crucial services such as case management, disease management, and drug utilization to ensure reduced prescription costs for insurers and insurance companies.
  • The rise in the number of people availing of insurance is driving the growth of the pharmacy benefit management market.
  • The countries covered in the pharmacy benefit management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

AssistRx Launches Advanced Gateway to Address Increasing Demands of Patient Support Programs

Retrieved on: 
Tuesday, June 20, 2023
Drug utilization review, PA, BV, Workflow, API, OOP, HCP, Patient, FTE, PBM, Digital, Nursing, Online shopping, Health insurance

Advanced Gateway was built in response to the growing demands placed upon patient support programs.

Key Points: 
  • Advanced Gateway was built in response to the growing demands placed upon patient support programs.
  • These programs – or hubs – were originally built to provide a single point of contact with patients to navigate reimbursement services.
  • Today these programs help patients and HCPs overcome access hurdles, address affordability concerns and support patient adherence through clinical services.
  • For many patient support programs, this results in multiple vendors, multiple portals and FTE-driven staffing models that are difficult to scale to HCP and patient needs.

Watson Rx Solutions Earns Two Prestigious Pharmaceutical Accreditations from URAC

Retrieved on: 
Monday, May 22, 2023
Other Retail, Online Retail, Technology, Other Health, Health, Specialty, Electronic Commerce, Pharmaceutical, Convenience Store, Retail, Internet, Drug utilization review, Pharmacy, Doctor of Pharmacy, Education, Nursing, Disclosure, OTCQB, URAC, Certification, Specialty pharmacy, Accreditation, Pharmacist

Dalrada Financial Corporation (OTCQB: DFCO , “Dalrada”), a problem-solving innovator that takes on complex, multi-disciplinary challenges in healthcare, clean energy, precision manufacturing, and technology, announced today that its pharmaceutical subsidiary, Watson Rx Solutions (Watson Rx), has received Specialty Pharmacy Accreditation and Mail Service Pharmacy Accreditation from the Utilization Review Accreditation Commission (URAC).

Key Points: 
  • Dalrada Financial Corporation (OTCQB: DFCO , “Dalrada”), a problem-solving innovator that takes on complex, multi-disciplinary challenges in healthcare, clean energy, precision manufacturing, and technology, announced today that its pharmaceutical subsidiary, Watson Rx Solutions (Watson Rx), has received Specialty Pharmacy Accreditation and Mail Service Pharmacy Accreditation from the Utilization Review Accreditation Commission (URAC).
  • Watson Rx is now permitted to display official URAC Certification Seals on its website and on printed materials.
  • “Earning these two full accreditations was certainly no easy task, but it was definitely worth it,” said Adam Myers, PharmD, Pharmacist of Watson Rx Solutions.
  • To learn more about Watson Rx Solutions and its continuing mission of providing comprehensive prescription management, education, nursing, and total health management, please visit www.watsonrxsolutions.com .

Zambon Announces New Data Highlighting Lifetime Burden of Illness in U.S. Patients with Bronchiolitis Obliterans Syndrome at ISPOR 2023

Retrieved on: 
Monday, May 8, 2023
Bronchiolitis, Drug utilization review, SLT, ISPOR, BOS, DLT, CMO, Life expectancy, HSCT, Pharmacoeconomics, Lung transplantation, HIV disease progression rates, Patient, Disease, Health, Hematopoietic stem cell transplantation, Pharmaceutical industry, Zambon

The study included adult BOS patients receiving a HSCT (rapid decliners), HSCT (gradual decliners), single lung transplant (SLT) or double lung transplant (DLT).

Key Points: 
  • The study included adult BOS patients receiving a HSCT (rapid decliners), HSCT (gradual decliners), single lung transplant (SLT) or double lung transplant (DLT).
  • The study showed that BOS patients have significant morbidity leading to reduced life expectancy and high direct medical expenses.
  • The average lifetime cost of BOS patients was $83,500 ranging from $27,900 to $96,900 across all sub-types.
  • Details about the 2023 ISPOR Meeting presentation are as follows:
    For more information on ISPOR's program, please visit the conference website at https://www.ispor.org/conferences-education/conferences/upcoming-confere...

FDB Vela™ Leader to Share Vision for Vastly Reducing Fill Times for Specialty Drug ePrescribing at NCPDP Annual Conference

Retrieved on: 
Thursday, May 4, 2023
Well, Pharmacy technician, Electronic prescribing, Doctor of Pharmacy, Pharmacy, The Westin Kierland Resort & Spa, Convention, Drug utilization review, Innovation, First Databank, MBA, FDB, Bigler, Accreditation Council for Pharmacy Education, Pharmacist, Patel, DUR, NCPDP, ACPE, National Primate Research Exhibition Hall, Patient, Navigo card, Great race, Frustration, Accreditation, Accreditation Council, HL7, Health, Conference, CPE, Safety, Meeting, Nursing

SOUTH SAN FRANCISCO, Calif., May 4, 2023 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, announced today that Lathe Bigler, vice president of clinical network services for FDB Vela™, will share insights at the NCPDP 2023 Annual Technology & Business Conference on how prescribers can quickly and simply electronically prescribe specialty medications based on new standards, processes, and tools to reduce fill time from weeks to hours (in many cases) and give patients greater access to care.

Key Points: 
  • Recently celebrating its first anniversary, FDB Vela empowers innovation, reduces barriers to participation, and increases the cost-effectiveness of electronic prescribing.
  • These advances help close gaps in care in the specialty medication process while improving prescriber efficiency, increasing patient adherence, and reducing frustration for all involved.
  • Bigler continued, "The hurdles involved in the current state of specialty drug prescribing cause widespread dissatisfaction among stakeholders.
  • Also speaking at the NCPDP 2023 Annual Technology & Business Conference will be Chirag Patel, PharmD, MBA, senior product manager for FDB.

New Clarivate Report Identifies Trends in Gene Therapy Poised to Impact Patients, Payers, Regulators and Developers

Retrieved on: 
Tuesday, May 2, 2023
Drug utilization review, Clarivate, CLVT, Eye, Quality of life, Intelligence, Benitec Biopharma, Organization, Patient, Risk, Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Health care, Medical device, Pharmaceutical industry

LONDON, May 2, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced the release of its new report, Making gene therapy work for patients, payers, regulators and developers: Five key trends in gene therapy approvals and access. The report explores the challenges and triumphs of gene therapy, with an eye on how developers are addressing risk and the need for multiple modalities and how payers are exploring alternative pay methods.

Key Points: 
  • The new report explores five key trends in gene therapy approvals, industry challenges and ways biopharmas can begin to address them.
  • Trends covered in the report are:
    The duration of therapeutic effects and questions about long-term safety persist as important uncertainties with gene therapies.
  • The inordinately high upfront costs of gene therapy have rendered the traditional reimbursement models (e.g., buy-and-bill) unfeasible for many insurers.
  • Read the report, Making gene therapy work for patients, payers, regulators and developers: Five key trends in gene therapy approvals and access, here .

New Clarivate Report Identifies Trends in Gene Therapy Poised to Impact Patients, Payers, Regulators and Developers

Retrieved on: 
Tuesday, May 2, 2023
Drug utilization review, Clarivate, CLVT, Eye, Quality of life, Intelligence, Benitec Biopharma, Organization, Patient, Risk, Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Health care, Medical device, Pharmaceutical industry

LONDON, May 2, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced the release of its new report, Making gene therapy work for patients, payers, regulators and developers: Five key trends in gene therapy approvals and access. The report explores the challenges and triumphs of gene therapy, with an eye on how developers are addressing risk and the need for multiple modalities and how payers are exploring alternative pay methods.

Key Points: 
  • The new report explores five key trends in gene therapy approvals, industry challenges and ways biopharmas can begin to address them.
  • Trends covered in the report are:
    The duration of therapeutic effects and questions about long-term safety persist as important uncertainties with gene therapies.
  • The inordinately high upfront costs of gene therapy have rendered the traditional reimbursement models (e.g., buy-and-bill) unfeasible for many insurers.
  • Read the report, Making gene therapy work for patients, payers, regulators and developers: Five key trends in gene therapy approvals and access, here .

Enlyte Releases Part 1 of Annual Pharmacy Solutions Drug Trends Report

Retrieved on: 
Wednesday, April 26, 2023
Wilson, Drug utilization review, Migraine, Doctor of Pharmacy, Prescription, Pharmacy, Outline, MBA, SAN, Dietary supplement, Health care, Pharmaceutical industry

SAN DIEGO, April 26, 2023 /PRNewswire/ -- Efforts to curtail overprescribing of opioids are seemingly having a positive impact in workers' comp, while increases in costly topical and migraine medications are driving pharmacy spend.

Key Points: 
  • These are some of the major findings in part 1 of Enlyte's 2023 Annual Pharmacy Solutions Drug Trends Report .
  • The goal of the full report, which will be issued in four segments over the next several months, is to provide an overall picture of drug utilization and cost trends in workers' comp to equip industry professionals with useful insights for pharmacy management.
  • "Analyzing in-network prescribing patterns identifies much of what pharmacy benefits managers are able to capture for comparable trend analysis, but it doesn't provide a complete picture," said Nikki Wilson, PharmD, MBA, senior director, clinical pharmacy solutions.
  • Among some of the findings from part 1 of this year's report, which focuses on retail and mail-order transactions billed through Enlyte Pharmacy Solutions in 2022 compared to 2021, is the continued decline of opioid usage.

Medical Pharmacy Trend Report™ delivers insights, forecasting in 12th edition

Retrieved on: 
Wednesday, December 14, 2022
Blue Cross, PMPM, Blue Shield, Forest Law Enforcement and Governance Program, Pharmacist, Commercial, Patient, Drug utilization review, Medicaid, COVID-19, Pharmacy, Health insurance, Pharmaceutical industry, Medicare

EAGAN, Minn., Dec. 14, 2022 /PRNewswire/ -- Magellan Rx Management (Magellan Rx), a Prime Therapeutics LLC (Prime) company, released its 12th annual Medical Pharmacy Trend Report™, featuring a comprehensive view of provider-administered medical benefit drug trends — one of the largest drivers of total specialty drug spend. This report offers detailed analysis of medical benefit drug claims, data benchmarks and current medical benefit drug management strategies.

Key Points: 
  • This report offers detailed analysis of medical benefit drug claims, data benchmarks and current medical benefit drug management strategies.
  • The report highlights how medical drug spend trend across Commercial, Medicare, and Medicaid lines of business has been influenced by the COVID-19 pandemic.
  • The Medical Pharmacy Trend Report supports those looking to prioritize strategies specific to specialty and medical pharmacy drugs."
  • The annual Medical Pharmacy Trend Report is just one of the ways Magellan Rx keeps the industry updated on the latest trends for medical benefit drugs.

Prime Therapeutics Presents Real-world Evidence-based Research

Retrieved on: 
Monday, October 10, 2022
Nexus, Adoption, Doctor of Pharmacy, Medicaid, Hospital, Medicine, Drug utilization review, CFTR, Blue Cross, PMPM, Twitter, Cystic fibrosis, Knowledge, Blue Shield, Infliximab, AMCP, Biosimilar, Medicare, Health, PBM, Breast cancer, Conditional sentence, Academy of Managed Care Pharmacy, Pharmacotherapy, Forest Law Enforcement and Governance Program, Academy, JAMA Network Open, Pharmacy, Solution, Healthcare, Medical imaging, Health insurance, Régence, MD

EAGAN, Minn., Oct. 10, 2022 /PRNewswire/ -- Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its integrated medical and pharmacy claims data to evaluate the real-world evidence in specialty medicine claims. Studies from these analyses will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting Oct. 11-14, 2022, in National Harbor, MD.

Key Points: 
  • EAGAN, Minn., Oct. 10, 2022 /PRNewswire/ -- Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its integrated medical and pharmacy claims data to evaluate the real-world evidence in specialty medicine claims.
  • Prime and Regence Health Plans stand for use of biosimilar products in place of the reference drug in most clinical circumstances.
  • Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well.
  • Prime provides total drug management solutions for health plans, employers, and government programs including Medicare and Medicaid.